Results 71 to 80 of about 4,843 (156)

Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES Trial [PDF]

, 2019
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death.
Hanotin, Corinne, Coca Payeras, Antonio, Goodman, Shaun G, Clemmensen, Peter, Peršić, Viktor, Roe, Matthew T., Schwartz, Gregory G., Harrington, Robert A, Pordy, Robert, ODYSSEY OUTCOMES Committees and Investigators, Bhatt, Deepak L., De Silva, Hithanadura Asita, Bruguera Cortada, Jordi, Andersen, Dorthe, Zeiher, Andreas M, White, Harvey, White, Harvey D, Moryusef, Angèle, Edelberg, Jay M., Schwartz, Gregory G, de Silva, H. Asita, Gislason, Gunnar, de Silva, H.Asita, Steg, P. Gabriel, Jukema, J.Wouter, Prieto, Juan C, Zeiher, Andreas M., Zijlstra, Laurien E, Davidsen, Flemming, Zeiher, Andreas Michael, Tomulić, Vjekoslav, Szarek, Michael, Jukema, J. Wouter, Prieto, Juan C., de Silva, H Asita, Mata Pericas, Laia, Jukema, J Wouter, Goodman, Shaun G., Gusi Tragant, Gabriel, Diaz, Rafael, Karpov, Yuri, Moryusef, Angle, White, Harvey D., Bhatt, Deepak L, Edelberg, Jay M, Bittner, Vera A., Steg, P.Gabriel, Cequier, Ángel, Steg, P Gabriel, Zijlstra, Laurien E., Videbaek, Lars, Reiner, Željko, García-Dorado, David, Harrington, Robert A., Bittner, Vera A, Universitat Autònoma de Barcelona, Roe, Matthew T   +56 more
core   +2 more sources

Glycemic Status and Effect of Immediate Intensive Statin on Mild Ischemic Stroke: A Subgroup Analysis of the INSPIRES Trial

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
Immediate‐intensive statin improves functional outcomes in non‐diabetic stroke patients: glycemic status modulates intensive statin treatment response. Early intensive statin therapy should be prioritized in stroke patients without diabetes, whereas alternative strategies may be needed for long‐standing T2DM to optimize functional recovery.
Lingling Jiang, Zihao Deng, Ying Gao, Xuan Wang, Yingying Yang, Tingting Wang, Yuesong Pan, Weiqi Chen, Yilong Wang   +8 more
wiley   +1 more source

Economic aspects of the cardiology program expansion of additional drugs provision by effective lipidlowering drugs for hypercholesterolemia control

Качественная клиническая практика
The federal program of preferential drug provision in cardiology shows its effectiveness. However, hypercholesterolemia (HCH) remains a significant problem in patients in whom high-dose statin therapy does not provide the target level of low-density ...
O. V. Obuhova, A. S. Bogomazova, A. N. Meshkov, M. V. Ezhov   +3 more
doaj   +1 more source

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

MedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao   +6 more
wiley   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, Volume 293, Issue 7, Page 2009-2021, April 2026.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell‐Based Therapies

The FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Graphical presentation of stem cell‐based therapies for arterial dysfunction, endothelial repair and regeneration strategies. SMC, smooth muscle cell. ABSTRACT Arterial regeneration represents a critical frontier in cardiovascular medicine, as progressive endothelial dysfunction, maladaptive vascular smooth muscle cell (SMC) plasticity, and chronic ...
Yun‐Yu Ma, Shu‐Yao Zhu, Yi Song
wiley   +1 more source

Alirocumab for the treatment of hypercholesterolaemia [PDF]

, 2017
Introduction: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are ...
Angela Albarosa Rivellese, ANNUZZI, GIOVANNI, BOZZETTO, LUTGARDA, RIVELLESE, ANGELA ALBAROSA, Giovanni Annuzzi, DELLA PEPA, GIUSEPPE, Lutgarda Bozzetto, Giuseppe Della Pepa   +7 more
core   +1 more source

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis

Frontiers in Pharmacology
BackgroundAlirocumab and evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors that significantly reduce the relative risk of cardiovascular events.
Leyu Xu, Leyu Xu, Ming Lei, Ming Lei, Liren Li, Liren Li, Yilei Li, Yilei Li, Chunping Gu, Chunping Gu, Ping Zheng, Ping Zheng   +11 more
doaj   +1 more source

Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels

Reviews in Cardiovascular Medicine
Background: A meta-analysis was conducted to determine whether the cardiovascular mortality and lipid-lowering effects of alirocumab and evolocumab are influenced by various baseline low-density lipoprotein cholesterol (LDL-C) levels.
Hui Ma, Wenfang Ma, Yang Liu, Lixing Chen, Peng Ding   +4 more
doaj   +1 more source

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes   +13 more
doaj   +1 more source